Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dermata Therapeutics Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. This means that each of the 2 pending actions is being reviewed independently by different personnel in different specialized units. The presence of 2 pending actions shows a small but distributed presence in the biotechnology sector.
The busiest examiner, ABRAHAM, AMJAD A, has 1 pending office action, which is half of the company's total pending volume. With 2 distinct art units involved, the company must adapt its responses to the specific requirements of two different pharmaceutical examination groups. This decentralized structure requires the legal team to manage 2 distinct examiners simultaneously. Practitioners should monitor the 2 distinct art units for differing procedural requirements that may impact the 2 pending office actions currently active.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABRAHAM, AMJAD A | 1 | 31.6% | +35.4% |
| BOATENG, AFUA BAMFOAA | 1 | 46.7% | +64.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18979328 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | ABRAHAM, AMJAD A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18979328 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | ABRAHAM, AMJAD A | — |
| 17628810 | COMPOSITIONS FOR THE TREATMENT OF CONDITIONS BY DERMAL FILLERS | BOATENG, AFUA BAMFOAA | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18979328 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | ABRAHAM, AMJAD A | 1663 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 12, 2024 |
| 17628810 | COMPOSITIONS FOR THE TREATMENT OF CONDITIONS BY DERMAL FILLERS | BOATENG, AFUA BAMFOAA | 1617 | §103 | Non-Final OA | — | Pending | Jan 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDermata Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Amjad A Abraham has the most, with 1 of Dermata Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
